MedTrace Logo

Progression Delaying Effect of Escitalopram in Alzheimer's Disease

NCT00702780 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2014-06-13

Study results available
· View outcomes & findings →

Summary

This study aimed to test whether escitalopram would slow the brain atrophy in patients with mild to moderate AD over the 52-week period.

Conditions

Interventions

DRUG

escitalopram

5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)

DRUG

placebo

5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Dong Young Lee, MD, PhD · Dept. of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine

  • Jong Inn Woo, MD, PhD · Dept. of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00702780 on ClinicalTrials.gov